Atlanta-Based Surgeon Dr. Michael Lebow Announces Nationwide Scholarship Supporting Undergraduate Students Pursuing Medical Careers
Founded by Dr. Michael Lebow, a board-certified vascular surgeon based in Atlanta, Georgia, the scholarship aims to highlight and encourage the next generation of leaders in healthcare. The award offers undergraduate students an opportunity to earn financial support by submitting a compelling 1,000-word essay responding to the prompt: 'What inspired you to pursue a career in medicine, and how do you envision making a meaningful impact in the healthcare industry?'
Dr. Michael Lebow brings a wealth of experience to this initiative, having dedicated his career to the diagnosis and treatment of complex vascular conditions such as peripheral artery disease, chronic venous insufficiency, and critical limb ischemia. His extensive medical training, which includes an MD from the University of Virginia School of Medicine and a vascular surgery fellowship at the University of Tennessee, underpins his dedication to supporting the academic and professional growth of medical students.
Open to undergraduate students currently enrolled in accredited colleges and universities within the United States, the scholarship is available to those pursuing pre-medical, nursing, or other healthcare-related studies. Eligible applicants must demonstrate academic excellence and a clear commitment to a future in medicine.
Applications will be evaluated based on originality, clarity, and the depth of insight expressed in the essay. Students are encouraged to draw from personal experiences, articulate meaningful goals, and offer innovative ideas for improving healthcare systems and patient care.
Dr. Michael Lebow's motivation to launch the scholarship stems from a lifelong passion for medicine and mentorship. Prior to his medical career, Dr. Michael Lebow served in the U.S. Army's 82nd Airborne Division, where he cultivated the leadership and discipline that now guide his work in both patient care and medical education. Today, he continues to contribute to surgical innovation and the development of future physicians through hands-on mentorship and advocacy for academic support.
The deadline to apply for the Dr. Michael Lebow Scholarship for Future Doctors is December 15, 2025. The winner will be publicly announced on January 15, 2026, via the official scholarship website.
Dr. Michael Lebow remains a respected figure in the medical community for his ongoing dedication to patient outcomes, surgical advancement, and education. By establishing this scholarship, Dr. Michael Lebow continues his mission to inspire and uplift future doctors who share his passion for making a lasting difference in healthcare.
For full eligibility details and application instructions, visit the official scholarship website at https://drmichaellebowscholarship.com or directly via https://drmichaellebowscholarship.com/dr-michael-lebow-scholarship/.
Media Contact
Company Name: Dr. Michael Lebow Scholarship
Contact Person: Dr. Michael Lebow
Email: Send Email
City: Atlanta
State: Georgia
Country: United States
Website: https://drmichaellebowscholarship.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Psychedelic Pharma Stock Surges on FDA Breakthrough
The psychedelic pharmaceutical sector continues gaining mainstream acceptance as regulatory barriers fall and medical applications expand beyond traditional treatments. With mental health disorders reaching epidemic proportions and conventional therapies showing limited efficacy for many patients, regulators are increasingly open to alternative treatments that were once considered fringe. This paradigm shift has created significant opportunities for companies positioned at the intersection of established pharmaceutical development and emerging psychedelic therapeutics. Shares of PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) are moving higher in Monday afternoon trading following the announcement that the company received FDA approval for its ketamine product, KETARx™, on August 8th for surgical pain management applications. This milestone represents a significant breakthrough for the specialty pharmaceutical company focused on unlocking ketamine's therapeutic potential across multiple medical conditions. The FDA approval positions PharmaTher to capitalize on the rapidly expanding ketamine market, which is currently valued at $750 million and projected to reach $3.42 billion by 2034, representing a compound annual growth rate of 16.4%. Ketamine stands out among psychedelic compounds as the only one included on the World Health Organization's Model List of Essential Medicines, providing additional validation for its therapeutic applications. The approval comes at an opportune time, as ketamine has been regularly listed on the FDA drug shortage list since February 2018, highlighting significant supply challenges in the market. The FDA has also issued compounding risk alerts regarding potential safety issues with non-approved ketamine products, creating demand for high-quality, FDA-approved alternatives like KETARx™. PharmaTher's FDA approval provides a strong foundation for expanding ketamine development across diverse therapeutic areas within the company's pipeline, including mental health conditions like depression, neurological disorders such as Parkinson's disease and ALS, and chronic pain management including Complex Regional Pain Syndrome. The market potential is demonstrated by SPRAVATO (esketamine), an FDA-approved depression treatment currently tracking a $1.6 billion sales run rate with guidance projecting $3 billion to $3.5 billion by 2027-2028. Additionally, the Veterans Health Administration currently approves and funds ketamine infusions for retired military personnel with depression, PTSD, and chronic pain, indicating established institutional acceptance. "Today marks a new chapter for PharmaTher," commented CEO Fabio Chianelli. "With FDA approval for ketamine now in hand, we are closer to realizing our goal of becoming a global leader in ketamine-based pharmaceuticals. This historic FDA approval for PharmaTher is a testament to years of dedicated development, signaling a new era of growth." U.S. shares of PHRRF are up 8.6% at $0.39, while Canadian shares of PHRM are ahead 8.0% at C$0.54 in Monday afternoon trading. Copyright © 2025 All rights reserved. Republication or redistribution of content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. View more of this article on About Media, Inc.: Founded in 1999, is one of North America's leading platforms for micro-cap insights. Catering to both Canadian and U.S. markets, we provide a wealth of resources and expert content designed for everyone—from beginner investors to seasoned traders. is rapidly gaining recognition as a leading authority in the micro-cap space, with our insightful content prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals. Want to showcase your company's story to a powerful network of investors? We can help you elevate your message and make a lasting impact. Contact us today. Contact: Media, Inc.
CTV News
3 hours ago
- CTV News
New Windsor-Essex hospital to be named after local family with $40-million donation
The New Windsor/Essex Acute Care Hospital will be named The Fancsy Family Hospital. Hospital officials announced Tuesday it is in recognition of a transformational gift of approximately $40 million from the estate of the late John Thomas Fancsy. The gift announcement at the site of the new hospital was attended by members of the Fancsy family, Premier Doug Ford, Minister of Health Sylvia Jones, local dignitaries and community leaders, along with John's two beloved Labradors. Hospital officials said this donation is the largest ever received by the Windsor Regional Hospital Foundation and the largest publicly-known gift in the Windsor-Essex Region. 'John's legacy gift is an extraordinary act of generosity,' said Karen Riddell, acting president and CEO and Chief Nursing Executive of Windsor Regional Hospital. 'We are immensely grateful and deeply honoured that the new hospital will bear the Fancsy family's name.' The Fancsy Family John was a brilliant engineer who went on to join the family business after graduating with a degree in mathematics from the University of Guelph and a degree in engineering from the University of Windsor. As a wine connoisseur, he joined his brother Stephen to found the award-winning Viewpointe Estate Winery in Harrow. John had a passion for supporting local endeavours and was instrumental in establishing Essex County as a premier destination for wine enthusiasts. The Fancsy family has deep ties to Windsor-Essex and played a vital role in shaping the local automotive sector. John's grandfather, Stephen Fancsy, co-founded major auto parts manufacturing companies, actively growing the sector and employing thousands of people late mother, Antoinette (née Goyeau), came from a family whose roots date back to early French settlement in Windsor-Goyeau Street spans what was once the Goyeau family farm. She also studied nursing and worked at Hôtel-Dieu Hospital, now Windsor Regional Hospital's Ouellette Campus. John's parents, Antoinette and Steve, had a long history of quiet generosity in the community, a value they instilled in their children from a young age. Like John, Antoinette included a generous gift to the new hospital in her will, and upon her passing in 2016, she was among the first to request that donations in her memory be made to the new hospital. Guided by his parents' selfless example, John channeled his deep passion for his community into making a meaningful and lasting impact on healthcare throughout the region. As a life-long resident of Windsor-Essex, John was always looking for ways to help this area grow and prosper, according to his five siblings. They say his generosity is something John learned from his parents, and they are proud the new hospital will be named in their honour. In recognition of this transformational gift, the Boards of Windsor Regional Hospital and Windsor Regional Hospital Foundation voted to name the new hospital 'The Fancsy Family Hospital.' WRH said this decision is consistent with other hospital namings across the province and the approach is supported by the Government of Ontario. While hospitals in the province are primarily paid for by the province, the local community is responsible for funding 10 per cent of hospital construction costs, as well as 100 per cent of the furniture, fixtures, equipment, parking and shell space.
National Post
3 hours ago
- National Post
Modern Health Welcomes New Chief Technology Officer and General Counsel
Article content New Data from Modern Health Reinforces Proven Model and Offers Fresh Insight into Evolving Workforce Needs Article content SAN FRANCISCO — Modern Health, a leading global workplace mental health platform, today announced the appointments of Chen Cheng as Chief Technology Officer and Erin Brown as General Counsel, along with other company momentum, as it accelerates its mission to make mental health care more accessible, personalized, and effective worldwide. Article content In her role as Chief Technology Officer, Chen Cheng will oversee the company's technology and further scale the platform to provide high-quality, clinically rigorous care across the globe. She brings more than a decade of experience in the health technology sector to Modern Health, including roles at Oscar Health and ZocDoc. As technology plays an increasingly critical role in expanding access to mental health care and support, evidenced by the growing engagement with virtual therapy, coaching, and digital tools, Chen will leverage her tech experience and leadership to help Modern Health advance its innovations. Article content Erin Brown joins Modern Health as General Counsel, bringing more than 20 years of legal experience across the health and benefits space. Brown has amassed a proven track record of guiding high-growth organizations through complex legal and regulatory environments. Prior to Modern Health, Brown was Senior Vice President and Associate General Counsel at Alight Solutions and, before that, Associate General Counsel at Aon Hewitt. Her expertise and strategic counsel will be key as Modern Health continues to expand its global footprint and innovate responsibly in a rapidly evolving industry. Article content 'Welcoming exceptional leaders like Chen and Erin marks an exciting step forward for Modern Health,' said Matt Levin, CEO of Modern Health. 'They each bring a powerful combination of industry expertise and a passion for making mental health care more accessible, personalized, and effective. Their leadership will accelerate our momentum as we scale our impact, drive innovation, and continue delivering meaningful outcomes for the workplaces we support worldwide.' Article content In addition to these appointments, other recent company momentum includes: Article content Modern Health has been named to the 2025 Inc. 5000 list of the fastest-growing private companies in America. The list highlights companies that have demonstrated significant revenue growth over a three-year period and serves as a benchmark for entrepreneurial success and a platform for recognizing the contributions of these businesses to the US economy. Modern Health launches ROI Study that proves mental health care pays off: According to a third-party analysis of 13,000+ members, the most significant savings (60% of total savings) in health care spend for employers come from reaching more employees earlier with support that fits their needs before symptoms escalate. Modern Health's evidence-based Adaptive Care Model delivers an estimated $2.39 return for every dollar invested, based solely on health care cost savings. These compelling findings underscore how Modern Health's Adaptive Care Model improves outcomes and drives down costs by supporting the whole workforce—not just those with severe mental health concerns. Peer-reviewed data shows Modern Health's global mental health model works anywhere: In one of the largest and most diverse real-world studies of its kind, Modern Health examined engagement and clinical outcomes among more than 33,000 members across seven global regions to understand not only how mental health needs vary across regions but also whether a single care model could truly work at a global scale. The study proves that achieving global scale requires more than a one-size-fits-all approach; it demands an adaptive, evidence-based model designed to deliver meaningful results across diverse regions and populations. Modern Health's latest study paints a stark picture of how Gen Z and Millennial employees are faring: In a study of 1,000 American professionals aged 18 to 44, the findings reveal a generation silently struggling under the weight of burnout, financial anxiety, and workplace systems that haven't kept pace with their needs. Among the most striking statistics: 75% blame financial stress for fueling burnout and hurting productivity, 79% sacrifice mental health to meet work demands, and 96% want access to preventative mental health support. The workplace report highlights a troubling reality: too many young workers are quietly pushing through mounting mental health challenges just to keep up at work, underscoring the urgent need to meet people earlier, with care that's proactive, adaptive, and designed to support the mental health of entire workforce populations. Launch of FlexEAP Challenges Outdated Employee Assistance Programs: Modern Health recently launched FlexEAP ('Flex'), a next-gen Employee Assistance Program (EAP) addressing the critical shortcomings of traditional EAPs by delivering rapid access to care, adaptive support extending far beyond crisis intervention, and a seamless, consistent global experience. The product combines Modern Health's Adaptive Care Model with an elite, global provider network to deliver a seamless, personalized mental health experience. Employees can access care, on average, within 24 hours, with fast, frictionless support across therapy, coaching, crisis intervention, and digital self-guided tools. Flex delivers superior outcomes and an upgraded, consumer-grade experience compared to traditional EAPs, while offering flexible pricing, customizable solutions, and risk-sharing based on utilization—empowering employers to better manage costs. Expanded Languages for Pathways: Modern Health is proud to offer its Pathways Collections, offering tailored one-on-one support around a variety of topics, including Workplace Well-being, Family Care, and Physical Well-Being, as a truly multilingual product. Now, members can connect with a Pathway Provider in six additional languages — Spanish, Dutch, Hindi, Portuguese, Japanese, and French. Article content About Modern Health Article content Modern Health is a global leader in adaptive mental health care, dynamically offering multi-modal mental health support that delivers meaningful outcomes at a sustainable, predictable cost. With therapy, psychiatry, coaching, community groups, self-guided tools, and crisis support, we dynamically create individualized care journeys to address a spectrum of mental health needs and preferences with culturally responsive providers in 200+ countries and territories and 80+ languages. Backed by peer-reviewed research and a proprietary blend of technology and live support, Modern Health delivers measurable outcomes, globally equitable access, and sustainable pricing. Our industry-leading Adaptive Care Model and dedicated, human centered, operationally tuned, customer success partners make us a trusted partner for organizations worldwide. Article content Article content Article content Article content Article content
